Gene patents were an abhorrent concept to Professor Mike Stratton, head of the British team that discovered the second breast cancer gene BrCa2, until he realised it was the only way to retain some control of a sensitive clinical tool. The British patent was granted this month and applications are pending in the US and Europe. The patent has already been sub-licensed, but for the first time the licensing agreement includes a binding ethical code of conduct.

The story begins in 1991 when geneticists from Berkeley, California located a gene linked to familial breast cancer (BrCa1) on chromosome 17. This wasn't the only breast cancer gene as not all predisposed families had it. So, funded by the Cancer Research Campaign, Stratton and a team from the Institute of Cancer Research in London hunted for another gene. Believing their set of DNA samples would not be powerful enough to highlight a new gene, they agreed to share samples with European and US groups, including one from the University of Utah.

In 1994, Stratton then located a new gene, BrCa2, on chromosome 13 and was about to embark on the hard work of isolating it when the Utah University group isolated BrCa1 and decided to set up a company called Myriad Genetics to develop its commercial potential. "At this point we decided that we could not collaborate with Utah. One reason was that it is hard to look into the future and see what could happen if a company owned a gene as interesting as BrCa2. Also, we would be in collaboration with a commercial enterprise, but our main research base continued to be samples from patients, none of whom had been asked if we could give their sample to a commercial company."

So Stratton and co decided to go it alone and what was a collaboration became a competition. "We thought this was the end of our chances of being successful because Myriad Genetics was very experienced and heavily financed. But we did it and published in December 1995 with about three- quarters of the sequence. In March Myriad published, confirming our findings, and completing the remaining quarter of the sequence."

Then came the crux. To develop a useful diagnostic test for familial breast cancer, both genes would need to be involved. Myriad had already moved to take out a patent on BrCa1 and was proving an aggressive player.

"If we didn't take out a patent on BrCa2, they could have a monopoly on that too and have the power to prevent anyone else developing a test. We are wary of gene patents, but decided it was the only safe thing to do to retain any control of the use of our findings."

Defending a patent is expensive and Stratton's funders, the Cancer Research Campaign didn't feel they could use charitable money to this end. So this year the patent was sold to a US biotech company, Oncomed, in a contract festooned with protective provisos. Chief among them - any test developed with BrCa2 must only be made available to people referred by a clinician expert in the management of familial breast cancer and who gives full pre- and post-test counselling.

There must also be absolutely no lay advertising: "We don't want any drumming up of business to increase people's concern."

In addition, Oncomed must sub-license the patent to all other commercial organ- isations that want to develop a test or therapy, providing they agree to be bound by the ethical code. Finally, no not-for-profit organ-isation, including the NHS, can be charged for using BrCa2 in any way. "We did the work in the public sector, financed by charitable donations in state institutions. We did not want to find them paying again." There's little doubt Oncomed will profit from the licence, but so too will CRC. For the record, says Stratton, he has waived all personal royalties.

How effective this ethical approach is remains to be seen. But Stratton believes trying to return science to an unpatentable Garden of Eden is a non-starter. "In the Eighties when few genes had been patented, it might have been possible to stop it, and there would still have been the incentive to produce diag- nostics and therapeutics because genes are the primary resource of modern medicine. With some genes patented, companies are only going to work on those they can get the patent on because they believe they need that degree of security. If we stop now, new unpatented genes will simply be ignored.

"From here on in, any scientists working with anything remotely developable will have to consider the implications of patents."

Suggested Topics
Arts and Entertainment
Reawakening: can Jon Hamm’s Don Draper find enlightenment in the final ‘Mad Men’?
tv reviewNot quite, but it's an enlightening finale for Don Draper spoiler alert
Arts and Entertainment
Breakfast Show’s Nick Grimshaw

Have you tried new the Independent Digital Edition apps?
Arts and Entertainment

ebooksNow available in paperback
Arts and Entertainment

Arts and Entertainment

Arts and Entertainment
'Youth' cast members Paul Dano, Jane Fonda, Harvey Keitel, Rachel Weisz, and Michael Caine pose for photographers at Cannes Film Festival
Arts and Entertainment
Adam West as Batman and Burt Ward and Robin in the 1960s Batman TV show

Arts and Entertainment
I am flute: Azeem Ward and his now-famous instrument
Arts and Entertainment
A glass act: Dr Chris van Tulleken (left) and twin Xand get set for their drinking challenge
TV review
Arts and Entertainment
MIA perform at Lovebox 2014 in London Fields, Hackney

Arts and Entertainment
Finnish punk band PKN hope to enter Eurovision 2015 and raise awareness for Down's Syndrome

Arts and Entertainment
William Shakespeare on the cover of John Gerard's The Herball or Generall Historie of Plantes

Arts and Entertainment

Game of Thrones review
Arts and Entertainment
Grayson Perry dedicates his Essex home to Julie

Potter's attempt to create an Essex Taj Mahal was a lovely treat

Arts and Entertainment
A scene from the original Swedish version of the sci-fi TV drama ‘Real Humans’
Arts and Entertainment
Hugh Keays-Byrne plays Immortan Joe, the terrifying gang leader, in the new film
filmActor who played Toecutter returns - but as a different villain in reboot
Arts and Entertainment
Charlize Theron as Imperator Furiosa in Mad Max: Fury Road
Arts and Entertainment
Jessica Hynes in W1A
tvReview: Perhaps the creators of W1A should lay off the copy and paste function spoiler alert
Arts and Entertainment
Power play: Mitsuko Uchida in concert

Arts and Entertainment
Dangerous liaisons: Dominic West, Jake Richard Siciliano, Maura Tierney and Leya Catlett in ‘The Affair’ – a contradictory drama but one which is sure to reel the viewers in
TV review
Arts and Entertainment
Richard Herring, pictured performing at the Edinburgh Fringe Festival two years ago
Arts and Entertainment
Music freak: Max Runham in the funfair band
Arts and Entertainment
film 'I felt under-used by Hollywood'
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    Abuse - and the hell that came afterwards

    Abuse - and the hell that follows

    James Rhodes on the extraordinary legal battle to publish his memoir
    Why we need a 'tranquility map' of England, according to campaigners

    It's oh so quiet!

    The case for a 'tranquility map' of England
    'Timeless fashion': It may be a paradox, but the industry loves it

    'Timeless fashion'

    It may be a paradox, but the industry loves it
    If the West needs a bridge to the 'moderates' inside Isis, maybe we could have done with Osama bin Laden staying alive after all

    Could have done with Osama bin Laden staying alive?

    Robert Fisk on the Fountainheads of World Evil in 2011 - and 2015
    New exhibition celebrates the evolution of swimwear

    Evolution of swimwear

    From bathing dresses in the twenties to modern bikinis
    Sun, sex and an anthropological study: One British academic's summer of hell in Magaluf

    Sun, sex and an anthropological study

    One academic’s summer of hell in Magaluf
    From Shakespeare to Rising Damp... to Vicious

    Frances de la Tour's 50-year triumph

    'Rising Damp' brought De la Tour such recognition that she could be forgiven if she'd never been able to move on. But at 70, she continues to flourish - and to beguile
    'That Whitsun, I was late getting away...'

    Ian McMillan on the Whitsun Weddings

    This weekend is Whitsun, and while the festival may no longer resonate, Larkin's best-loved poem, lives on - along with the train journey at the heart of it
    Kathryn Williams explores the works and influences of Sylvia Plath in a new light

    Songs from the bell jar

    Kathryn Williams explores the works and influences of Sylvia Plath
    How one man's day in high heels showed him that Cannes must change its 'no flats' policy

    One man's day in high heels

    ...showed him that Cannes must change its 'flats' policy
    Is a quiet crusade to reform executive pay bearing fruit?

    Is a quiet crusade to reform executive pay bearing fruit?

    Dominic Rossi of Fidelity says his pressure on business to control rewards is working. But why aren’t other fund managers helping?
    The King David Hotel gives precious work to Palestinians - unless peace talks are on

    King David Hotel: Palestinians not included

    The King David is special to Jerusalem. Nick Kochan checked in and discovered it has some special arrangements, too
    More people moving from Australia to New Zealand than in the other direction for first time in 24 years

    End of the Aussie brain drain

    More people moving from Australia to New Zealand than in the other direction for first time in 24 years
    Meditation is touted as a cure for mental instability but can it actually be bad for you?

    Can meditation be bad for you?

    Researching a mass murder, Dr Miguel Farias discovered that, far from bringing inner peace, meditation can leave devotees in pieces
    Eurovision 2015: Australians will be cheering on their first-ever entrant this Saturday

    Australia's first-ever Eurovision entrant

    Australia, a nation of kitsch-worshippers, has always loved the Eurovision Song Contest. Maggie Alderson says it'll fit in fine